Loading stock data…
$9.79-0.40 (-3.97%)
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
Xeris Biopharma Holdings, Inc. in the Healthcare sector is trading at $9.79 with a market capitalization of $1.4B. Wall Street consensus targets $12.86 (7 analysts), implying a +31.3% move over the next 12 months. The stock is currently 14% below its 52-week high of $11.33, remaining 33.8% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $92.10M↑ | $83.13M↓ | $85.81M↑ | $74.38M↑ | $71.54M |
| Gross Profit | $79.59M↑ | $72.55M↓ | $74.86M↑ | $63.38M↑ | $59.64M |
| Operating Income | $5.17M↓ | $7.92M↓ | $16.77M↑ | $6.73M↑ | $4.48M |
| Net Income | -$31.10M↓ | $2.23M↓ | $11.08M↑ | $621,000↑ | -$1.93M |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for ...